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Background: Thyroid cancer has become themost common cancer in Korea. Generally,
thyroid cancer patients have a good prognosis; however, 15–20% of patients experience
recurrence or distant metastasis or are refractory to standard treatment. We assessed
the safety of sorafenib and lenvatinib in patients with advanced or metastatic radioactive
iodine-refractory differentiated thyroid cancers (DTC) consecutively treated at a tertiary
center in South Korea.
Methods: We retrospectively reviewed the charts of all consecutive patients with DTC
treated during ≥6 months with lenvatinib (February 2016–April 2018) and sorafenib
(January 2014–April 2018) at Gangnam Severance Hospital. Patients were treated
according to the prescribing information of each drug and were followed up for 2 months.
We evaluated the adverse events (AEs) reported with each drug.
Results: A total of 71 medical records (lenvatinib, n = 23; sorafenib, n = 48) were
reviewed. The most common histological types were papillary thyroid cancer (69.0%) and
follicular thyroid cancer (22.5%). All patients (n= 23) started lenvatinib at a dose of 20mg;
41.7% of sorafenib-treated patients received an initial dose of 800mg daily. Four (17.4%)
lenvatinib-treated patients and 26 (54.2%) sorafenib-treated patients required treatment
discontinuation. The most common AEs of any grade in the lenvatinib group were
diarrhea (82.6%), hypertension (78.3%), hand-foot skin reaction (56.5%), weight loss
(52.2%), proteinuria (47.8%), and anorexia (43.5%). In the sorafenib group, these were
hand-foot skin reaction (87.5%), diarrhea (62.5%), anorexia (60.4%), alopecia (56.3%),
mucositis (52.1%), weight loss and generalized weakness (each, 50%), and hypertension
(43.8%). The incidence of hand-foot skin reaction, alopecia, and rash of any grade was
significantly lower (P = 0.003, P = 0.017, and P = 0.017) in patients treated with
lenvatinib compared with those treated with sorafenib. The incidence of hypertension,
QT prolongation, and proteinuria of any grade was significantly higher (P = 0.006,
P= 0.038, and P< 0.001) in patients treated with lenvatinib compared with those treated
with sorafenib. Seven deaths occurred, which were attributed to disease progression.
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Conclusions: No new safety concerns were identified for either drug. Most AEs were
managed with dose modification and medical therapy. AEs such as hypertension and
proteinuria warrant close monitoring.
Keywords: adverse effects, chart review, differentiated thyroid cancer, lenvatinib, refractory thyroid cancer, safety,
sorafenib, tyrosine kinase inhibitors
INTRODUCTION
In recent decades, the incidence of thyroid cancer has increased
considerably both worldwide (1) and in Korea (2). In Korea,
the incidence of thyroid cancer increased by 22.3% per year
in both sexes, and thyroid cancer is the most common cancer
since 2009 (2). The most common histological subtypes of
thyroid cancer are papillary thyroid cancer (PTC), follicular
thyroid cancer (FTC), poorly differentiated thyroid cancer, and
anaplastic thyroid cancer. PTC and FTC are collectively classified
as differentiated thyroid cancers (DTC).
Although most thyroid cancer patients have good overall
survival, about 15–20% of patients experience recurrence or
distant metastasis (3–5), are refractory to standard treatment
(6, 7), or experience considerable treatment-related toxicities.
There are limited therapeutic options for such patients with
advanced thyroid cancer and poor prognosis (7); thus, safe and
tolerable treatment options are needed.
The molecular signals involved in the pathogenesis of
thyroid cancer are the RAS and BRAF/MEK/ERK signaling
pathways; ligand-independent RET/PTC receptor tyrosine kinase
activation; and pathways involving vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), and their
receptors (8, 9). Lenvatinib is a multitargeted tyrosine kinase
inhibitor (TKI) that targets VEGF receptors 1–3, fibroblast
growth factor receptors (FGFR) 1–4, PDGF receptor a, RET, and
KIT (10, 11). Lenvatinib was shown to be efficacious in patients
with advanced, progressive DTC refractory to radioactive iodine
in the randomized phase 3 SELECT trial (12), with a median
progression-free survival (PFS) of 18.3 months compared with
3.6 months in the placebo group. Based on the results of the
SELECT trial, lenvatinib was approved to treat patients with
advanced and progressive DTC refractory to radioactive iodine
(RAI). In Korea, lenvatinib was approved and launched into the
market in February 2016.
Sorafenib is a multitargeted TKI that blocks the activity of
Raf serine/threonine kinase isoforms, VEGF receptor-2 and−3,
PDGF receptor β, c-KIT, FMS-like tyrosine kinase (FLT)-3, and
RET, resulting in inhibition of tumor angiogenesis and cell
proliferation (13–15). In the phase 3 DECISION trial, sorafenib
treatment significantly improved PFS compared with placebo
(P < 0.0001; median 10.8 vs. 5.8 months, respectively) (16).
Abbreviations: AE, adverse event; DTC, differentiated thyroid cancer; ECOG,
Eastern Cooperative Oncology Group; FTC, follicular thyroid cancer; PDGF,
platelet-derived growth factor; PFS, progression-free survival; PTC, papillary
thyroid cancer; QoL, quality of life; RAI, radioactive iodine; TKI, tyrosine kinase
inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial
growth factor receptor.
Sorafenib was approved and launched into the market in Korea
in January 2014.
As lenvatinib was recently approved for the treatment of DTC,
there is a lack of efficacy and safety data. The mechanism of
action of lenvatinib differs from that of sorafenib, and thus, it
may have a different safety profile. The lack of real-world clinical
data and the presumed differences in safety profiles may preclude
clinicians from using lenvatinib in their routine clinical practice.
The present study aimed to evaluate the safety of lenvatinib and
sorafenib in consecutive patients with advanced or metastatic
RAI-refractory DTC treated at a tertiary center in a real-world
clinical practice setting in Korea.
METHODS
Study Design, Setting, and Treatment
This was a retrospective medical chart review conducted in
Gangnam Severance Hospital, Seoul, South Korea. Charts of
patients treated with lenvatinib from February 2016 to April
2018 and those of patients treated with sorafenib from January
2014 to April 2018 were retrospectively reviewed. Sorafenib was
used to treat all patients prior to lenvatinib becoming available
in hospitals in February 2016. This study focused only on the
adverse events (AEs) reported with each treatment.
Treatments were prescribed by the treating physician
according to the prescribing information for each drug
(LENVIMA R© [lenvatinib] capsules, for oral use. Highlights of
prescribing information 20181; NEXAVAR R© [sorafenib] tablets,
oral. Highlights of prescribing information 20132), based on
their judgment and local practices. For patients who underwent
treatment for a minimum of 6months, the follow-up interval was
2 months, and all patients had three or more follow-up visits.
The study was carried out in accordance with the principles
laid out in the World Medical Association’s Declaration
of Helsinki, Good Clinical Practice, and associated Korean
regulations. This study was approved by the Institutional
Review Board of Gangnam Severance Hospital (approval number
2017-0116-004). As data were obtained retrospectively, patient
identities remained anonymous, and informed consent is not
mandatory for retrospective studies in Korea, the institutional
review board waived the need for informed consent.
1Available online at: http://www.lenvima.com/pdfs/prescribing-information.pdf
(accessed August 8, 2018)
2Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/
021923s016lbl.pdf (accessed August 8, 2018)
Frontiers in Endocrinology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 384
Kim et al. TKI Safety in Korean Center
Patients
In this study, we included all consecutive patients with DTC who
were treated with lenvatinib or sorafenib for more than 6 months
at our center during the designated chart review period.
TKI Use
TKI use was assessed in terms of initial and final doses
administered, as well as dose reductions, drug interruptions, or
discontinuations because of AEs.
Safety
To assess the safety of the treatment, adverse event data
were obtained retrospectively from hospital records and were
classified according to the National Cancer Institute Common
Terminology Criteria for Adverse Events v4.0. Safety assessments
also included physical examination, electrocardiogram, and
laboratory testing (including blood cell count, liver and renal
function, electrolyte levels, and proteinuria), during follow-
up visits.
Statistical Analysis
The sample size was not calculated or preplanned as this study
aimed to evaluate the records of all consecutive patients with
DTC treated at our center during the study period. Descriptive
analyses were performed. Quantitative data are expressed as
absolute numbers and median or mean. Qualitative data are
expressed as a percentage of the entire population (n [%]). Data
in the two treatment groups were compared using the Student’s
t-test, the chi-square test, and Fisher’s exact test, as appropriate.
The statistical software used to perform the statistical analysis in
this study was SPSS version 22 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patients
In total, 71 medical records of patients with advanced or
metastatic DTC consecutively treated with lenvatinib (n= 23) or
sorafenib (n= 48) at our center were analyzed. The main patient
demographic and clinical characteristics are shown in Table 1.
TABLE 1 | Patient demographic and clinical characteristics.
Patients characteristics Lenvatinib
(N = 23)
Sorafenib
(N = 48)
Total
(N = 71)
P-value
Age at the Start of Treatment, Years
Median (range) 59.7 (38.9–74.4) 62.0 (32.6–79.0) 61.7 (32.6–79.0) 0.961
≥60 years 11 (47.8) 29 (60.4) 40 (56.3) 0.317
Sex 0.839
Male 9 (39.1) 20 (41.7) 29 (40.8)
Female 14 (60.9) 28 (58.3) 42 (59.2)
Metastases 0.743
Locally advanced 3 (13.0) 5 (10.4) 8 (11.3)
Distant 20 (87.0) 43 (89.6) 63 (88.7)
ECOG performance status 0.971
0 7 (30.4) 16 (33.3) 23 (32.3)
1 12 (52.2) 24 (50.0) 36 (50.7)
2 4 (17.4) 8 (16.7) 12 (17.0)
Histology 0.415
Papillary 14 (60.9) 35 (72.9) 49 (69.0)
Follicular 7 (30.5) 9 (18.8) 16 (22.5)
Hürthle cell 0 1 (2.1) 1 (1.4)
Poorly differentiated 2 (8.6) 3 (6.3) 5 (7.1)
Most Common Metastatic Lesion Sites (Multiple)
Lung 18 (78.3) 41 (85.4) 59 (83.1) 0.451
Bone 9 (39.1) 16 (33.3) 25 (35.2) 0.632
Brain 0 3 (6.3) 3 (4.2) 0.221
Liver 1 (4.3) 2 (4.2) 3 (4.2) 0.972
Other (renal, mediastinal) 2 (8.7) 2 (4.2) 4 (5.6) 0.439
Previous Treatment
Cumulative radioiodine activity,
median (range), mCi
665 (30–4000) 730 (30–1580) 710 (30–4000) 0.966
Previous systemic therapy 10 (43.5) 0 10 (43.5) 0.018
Data in the table are presented as n (%), unless otherwise stated.
ECOG, Eastern Cooperative Oncology Group.
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The median age of all patients at the start of treatment was
61.7 (32.6–79.0) years, which was similar among those treated
with lenvatinib and sorafenib; 56.3% of patients were 60 years
of age or older. Of the patients with DTC in the lenvatinib-
and sorafenib-treated groups, 39.1 and 41.7% of patients were
men. Distant metastases were observed in 88.7% of patients, and
locally advanced DTC was identified in 11.3% of patients. The
most common histological types were PTC (69.0%), followed by
FTC (22.5%), and poorly differentiated thyroid cancer (7.1%). All
patients had received previous RAI, and the median cumulative
RAI was 665 mCi (30–4000) among those treated with lenvatinib
and 730 mCi (30–1580) among those treated with sorafenib.
Systemic therapy had been previously administered to 10 (43.5%)
patients treated with lenvatinib; none of those treated with
sorafenib had received prior systemic therapy.
TKI Use
The use of lenvatinib and sorafenib during the study period is
shown in Table 2. All patients (n = 23) started lenvatinib at the
dose of 20mg. Among sorafenib-treated patients, 41.7% received
an initial dose of 800mg daily. At the end of the treatment,
only 14.6% of patients were receiving the 800mg daily dose; 41.7
and 43.8% of patients were receiving reduced sorafenib doses of
≤400mg daily and 600mg daily, respectively.
TABLE 2 | Use of lenvatinib and sorafenib during the study period.
Lenvatinib N = 23
n (%)
Initial lenvatinib dose (20mg) 23 (100)
Final Lenvatinib Dose
10mg daily 7 (30.4)
14mg daily 2 (8.7)
20mg daily 14 (60.9)
Dose reduction for AEs 8 (34.8)
Discontinuation of Lenvatinib
AE 1 (4.3)
Disease progression 0
Death 2 (8.7)
Financial issues 1 (4.3)
Sorafenib N = 48
n (%)
Initial Sorafenib Dose
≤400mg daily 12 (25.0)
600mg daily 16 (33.3)
800mg daily 20 (41.7)
Final Sorafenib Dose
≤400mg daily 20 (41.7)
600mg daily 21 (43.8)
800mg daily 7 (14.6)
Dose reduction for AEs 27 (56.3)
Discontinuation of Sorafenib
AE 4 (8.3)
Disease progression 17 (35.4)
Death 5 (10.4)
AE, adverse event.
Eight (34.8%) lenvatinib-treated patients required dose
reductions because of AE onset (some patients reported more
than one AE: hand-foot skin reactions, n = 3; weight loss, n =
3; QT prolongation, n = 1; hypertension, n = 2; proteinuria, n
= 3), while 27 (56.3%) sorafenib-treated patients required dose
reduction because of AE onset (some patients reportedmore than
one AE: hand-foot skin reactions, n = 24; general weakness, n
= 7; headache, n = 2; hypertension, n = 2; weight loss, n =
7). Four (17.4%) lenvatinib-treated patients required treatment
discontinuation; the reasons were death in two cases (8.7%), an
AE in one case (4.3%), and financial issues in another case (4.3%).
Twenty-six (54.2%) sorafenib-treated patients required treatment
discontinuation; the reasons were disease progression in 17 cases
(35.4%), death in five cases (10.4%), and AEs in four cases (8.3%;
coronary artery occlusion, n= 1; weight loss, n= 1; uncontrolled
hypertension, n= 1; and cerebrovascular disease, n= 1).
Safety
The safety and tolerability findings are shown in Table 3,
4. In the lenvatinib group, the most common AEs of any
grade with an incidence above 40% were diarrhea (82.6%),
hypertension (78.3%), hand-foot skin reaction (56.5%), weight
loss (52.2%), proteinuria (47.8%), and anorexia (43.5%). In the
sorafenib group, the most common AEs of any grade with
an incidence above 40% were hand-foot skin reaction (87.5%),
diarrhea (62.5%), anorexia (60.4%), alopecia (56.3%), mucositis
(52.1%), weight loss and generalized weakness (each, 50%), and
hypertension (43.8%).
When comparing the incidence of AEs of any grade between
patients treated with lenvatinib and those treated with sorafenib,
TABLE 3 | Comparison of the incidence of adverse events of any grade in
patients treated with lenvatinib vs. those treated with sorafenib.
Adverse events
N = 71
Lenvatinib
N = 23
n (%)
Sorafenib
N = 48
n (%)
P-value
Hand-foot skin reaction 13 (56.5) 42 (87.5) 0.003
Diarrhea 19 (82.6) 30 (62.5) 0.086
Alopecia 6 (26.1) 27 (56.3) 0.017
Rash 2 (8.7) 17 (35.4) 0.017
Mucositis 29 (39.1) 25 (52.1) 0.307
Hypertension 18 (78.3) 21 (43.8) 0.006
QT prolongation 2 (8.7) 0 0.038
Generalized weakness 9 (39.1) 24 (50) 0.390
Headache 1 (4.3) 5 (10.4) 0.390
Leucopenia 0 4 (8.3) 0.154
Anemia 1 (4.3) 4 (8.3) 0.539
Hepatitis 0 1 (2.1) 0.486
Anorexia 10 (43.5) 29 (60.4) 0.179
Weight loss 12 (52.2) 24 (50.0) 0.864
Cerebrovascular accident 1 (4.3) 2 (4.2) 0.972
Renal impairment 2 (8.7) 1 (2.1) 0.195
Proteinuria 11 (47.8) 0 <0.001
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significantly fewer patients treated with lenvatinib had a hand-
foot skin reaction (56.5 vs. 87.5%; P = 0.003), alopecia (26.1
vs. 56.3%; P = 0.017), and rash (8.7 vs. 35.4%; P = 0.017)
(Table 3). Significantly more patients treated with lenvatinib had
hypertension (78.3 vs. 43.8%; P = 0.006) (Table 3). Further,
QT prolongation (2 [8.7%]) and proteinuria (11 [47.8%]) were
only reported in patients treated with lenvatinib, and these
between-group differences were significant (P = 0.038 and P <
0.001, respectively) (Table 3). In patients with QT prolongation,
electrolyte levels and blood glucose were normal and, in some
patients, no changes in thyroid function were observed.
When comparing the incidence of Grade ≥3 AEs between
patients treated with lenvatinib and those treated with sorafenib,
significantly less patients treated with lenvatinib presented a
Grade ≥3 hand-foot skin reaction (30.4 vs. 66.7%; P = 0.004),
but significantly more patients treated with lenvatinib presented
Grade ≥3 hypertension (73.9 vs. 31.3%; P = 0.001) (Table 4).
Grade≥3 QT prolongation (2 [8.7%]) and proteinuria (2 [8.7%])
were only reported in patients treated with lenvatinib, and these
between-group differences were significant (P = 0.038 and P <
0.001, respectively) (Table 4). There were two deaths among the
patients treated with lenvatinib, and there were five deaths among
the patients treated with sorafenib; all deaths were determined
to be due to disease progression and not drug-related. In both
groups, all deaths were attributed to disease progression and were
not considered to be related to treatment.
DISCUSSION
As there is a lack of real-world data on the use of TKIs, specifically
lenvatinib, and sorafenib, for the treatment of DTC, which may
preclude the use of these drugs in clinical practice, we conducted
this retrospective chart review study to assess and compare the
TABLE 4 | Comparison of the incidence of Grade ≥3 adverse events in patients
treated with lenvatinib vs. those treated with sorafenib.
Adverse events
N = 71
Lenvatinib
N = 23
n (%)
Sorafenib
N = 48
n (%)
P-value
Hand-foot skin reaction 7 (30.4) 32 (66.7) 0.004
Diarrhea 1 (4.3) 7 (14.6) 0.202
Rash 0 2 (4.2) 0.321
Mucositis 1 (4.3) 3 (6.3) 0.745
Hypertension 17 (73.9) 15 (31.3) 0.001
QT prolongation 2 (8.7) 0 0.038
Generalized weakness 1 (4.3) 6 (12.5) 0.281
Leucopenia 0 2 (4.2) 0.321
Hepatitis 0 1 (2.1) 0.486
Anorexia 1 (4.3) 10 (20.8) 0.072
Weight loss 0 4 (8.3) 0.154
Cerebrovascular accident 0 2 (4.2) 0.321
Renal impairment 0 0
Proteinuria 2 (8.7) 0 0.038
safety of both drugs in patients with DTC treated at a single
third-level-of-care center in Korea.
In a real-world clinical setting, drugs are used according
to comprehensive patient situations. Meanwhile, in clinical
trials, strict compliance to protocol is prioritized. In routine
clinical practice, physicians can manage AEs by adjusting the
drug dosage, implementing treatment interruption periods, or
adjusting the follow-up period once they take into consideration
all the clinical aspects of each patient individually. Thus, the
results of the present study are meaningful in that they provide
insight into the safety profile of these TKIs in a real-world setting
in patients with DTC who are not subject to strict eligibility
criteria or strict clinical study conditions.
The AEs of any grade reported in patients treated with
lenvatinib in the present study (diarrhea [82.6%], hypertension
[78.3%], hand-foot skin reaction [56.5%], weight loss [52.2%],
proteinuria [47.8%], and anorexia [43.5%]) were comparable
with those reported in the SELECT trial (hypertension [67.8%],
diarrhea [59.4%], fatigue or asthenia [59.0%], decreased
appetite [50.2%], decreased weight [46.4%], and nausea
[41.0%]) (12). Previous studies of patients treated with
lenvatinib showed an increased risk of hypertension and
proteinuria (17, 18).
The AEs reported in patients treated with sorafenib in the
present study (hand-foot skin reaction [87.5%], diarrhea [62.5%],
anorexia [60.4%], alopecia [56.3%], mucositis [52.1%], weight
loss and generalized weakness [each, 50%], and hypertension
[43.8%]) were comparable with those reported in the DECISION
trial (hand-foot skin reaction [76.3%], diarrhea [68.6%], alopecia
[67.1%], and rash or desquamation [50.2%]) (16). No new safety
concerns were identified for either drug.
We observed some key differences in the safety profiles
of lenvatinib and sorafenib. The incidence of hand-foot skin
reaction, alopecia, and rash of any grade was significantly
lower in patients treated with lenvatinib compared with those
treated with sorafenib. The incidence of hypertension, QT
prolongation, and proteinuria of any grade was significantly
higher in patients treated with lenvatinib compared with those
treated with sorafenib.
Dermatologic toxicities, such as rash, erythema, pruritus,
acneiform rash, paronychia, telangiectasia, alopecia, changes
in hair growth or pigmentation, skin discoloration, xerosis,
and hand-foot skin reaction, particularly with TKIs targeting
vascular endothelial growth factor receptor (VEGFR) or EGFR
pathways, have been well-characterized (19–21). Hand-foot
skin reaction and rash are symptomatic AEs that can affect
the quality of life (QoL) of patients and hinder patient
adherence to the treatment. A previous study on the impact
of dermatologic AEs secondary to TKI treatment on QoL
reported that dermatologic toxicities, including rash, xerosis,
paronychia, and pruritus, adversely affected QoL. Among these
AEs, rash was associated with the greatest decrease in QoL (22).
Another study focusing on the clinical psychologist’s perspective
reported that dermatologic toxicities associated with TKIs had
an impact on patients’ physical, functional, emotional, and
social well-being. Patients reported feeling worry, frustration,
and depression because of their dermatologic symptoms (23).
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Such dose-dependent skin toxicities may lead to physical and
psychosocial discomfort, which can result in dose reduction or
treatment interruption (20).
Hypertension is another well-documented, characterized AE
resulting from VEGFR inhibition (24). However, hypertension
is generally asymptomatic and can be clinically managed with
medication. A recently published exploratory analysis of the
phase 3 lenvatinib SELECT trial data showed that although
hypertension was indeed a clinically significant AE, treatment-
related hypertension was significantly correlated with improved
outcomes in patients with radioiodine-refractory DTC (24).
Dose reductions due to AEs were lower in patients
treated with lenvatinib (34.8%) compared with sorafenib
(56.3%). Thus, this difference in the safety profile of
lenvatinib and sorafenib may have been the reason why
the rate of dose reductions due to AEs was lower in
patients treated with lenvatinib compared with sorafenib.
Another plausible explanation for the lower dose reduction
rate due to AEs in this patient group is that 100% of
patients treated with lenvatinib initiated therapy at a dose
of 20 mg.
All patients treated with lenvatinib (100%) received an initial
dose of 20mg (83% of the recommended initial dose). In
contrast, 41.7% of the patients treated with sorafenib received
an initial dose of 800mg (100% of the recommended initial
dose), 33.3% received an initial dose of 600mg (75% of the
recommended initial dose), and 25% received an initial dose
of <400mg (<50% of the recommended initial dose). The
main reason most patients initiated lenvatinib treatment at
a dose of 20mg was economic burden. As of August 2017,
the treatment costs of lenvatinib are being reimbursed by
the National Health Institute of Korea (25). Furthermore,
Kiyota et al. (28) conducted a subanalysis of Japanese patients
enrolled in the global SELECT study, which revealed higher
rates of certain adverse events such as hypertension and
proteinuria, as well as a higher rate of dose reduction
compared with non-Japanese patients. These results suggest
that patients of east Asian descent may benefit from initiating
lenvatinib at a lower dose, rather than undergoing subsequent
dose reduction.
None of the patients treated with lenvatinib discontinued
treatment because of disease progression. However, 35.4% of
patients treated with sorafenib had to discontinue sorafenib
treatment because of disease progression. The present results
were comparable with those reported in two previous studies on
lenvatinib in real-world clinical practice (26, 27).
STUDY LIMITATIONS
This study had several limitations, including the limited
generalizability of the results, problematic verification
of information, difficulty establishing cause and effect,
variation in the quality of information recorded by medical
professionals, and other limitations inherent to the chart
review design of the study. Further, in about half of the
patients, lenvatinib was used as second-line treatment, while
sorafenib was only used in naïve patients because of the market
launch and reimbursement gap. This affected the number
of patients in each group and may have also affected the
safety results.
CONCLUSIONS
AEs can occur frequently with lenvatinib and sorafenib;
however, we observed that dermatologic AEs were significantly
more frequent with sorafenib than lenvatinib. Similarly,
hypertension was significantly more frequent with lenvatinib
than sorafenib. Overall, safety outcomes were in line with
previously reported clinical trial data, and most AEs were
managed with dose modification and medical therapy. Most
AEs of lenvatinib were manageable and observed within the
first 6 months of treatment. Thus, it is important to monitor
patients, particularly during the initial treatment period. In
patients treated with lenvatinib, AEs such as hypertension
and proteinuria warrant close monitoring and management
if necessary.
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